Khan N, Antonini A, Parkes D, Dahlitz M J, Meier-Ewert K, Weindl A, Leenders K L
PET Department, Paul Scherrer Institute, Villigen, Switzerland.
Neurology. 1994 Nov;44(11):2102-4. doi: 10.1212/wnl.44.11.2101.
We investigated in vivo D2 receptor binding using 11C-raclopride and PET in the striatum of 17 subjects with the narcoleptic syndrome. Putamen and caudate nucleus 11C-raclopride uptake was comparable in the total patient group and controls, and the tracer uptake was similar in the HLA-DR2-positive (n = 12) and HLA-DR2-negative (n = 5) narcoleptic subjects. There was a significant increase in 11C-raclopride uptake in the putamen of narcoleptic subjects older than 31 years (n = 11) when compared with age-matched controls (n = 15). There was no evidence of involvement of the striatal D2 dopaminergic neurotransmitter system in the basic pathophysiology of the narcoleptic syndrome despite an age-related increase in putaminal 11C-raclopride uptake.
我们使用11C-雷氯必利和正电子发射断层扫描（PET）对17名发作性睡病综合征患者的纹状体进行了体内D2受体结合研究。在整个患者组和对照组中，壳核和尾状核的11C-雷氯必利摄取量相当，且在HLA-DR2阳性（n = 12）和HLA-DR2阴性（n = 5）的发作性睡病患者中，示踪剂摄取情况相似。与年龄匹配的对照组（n = 15）相比，31岁以上的发作性睡病患者（n = 11）壳核中的11C-雷氯必利摄取量显著增加。尽管壳核中11C-雷氯必利摄取量随年龄增加，但没有证据表明纹状体D2多巴胺能神经递质系统参与发作性睡病综合征的基本病理生理过程。
